about
Nanodiamond-mitoxantrone complexes enhance drug retention in chemoresistant breast cancer cellsEpirubicin-adsorbed nanodiamonds kill chemoresistant hepatic cancer stem cells.ST3GAL1-Associated Transcriptomic Program in Glioblastoma Tumor Growth, Invasion, and Prognosis.Epigenetics in cancer stem cells.Cryopreservation of cancer-initiating cells derived from glioblastoma.Nanodiamond-Manganese dual mode MRI contrast agents for enhanced liver tumor detection.Identification and Optimization of Combinatorial Glucose Metabolism Inhibitors in Hepatocellular Carcinomas.TIP60 inhibits metastasis by ablating DNMT1-SNAIL2-driven epithelial-mesenchymal transition program.A distinct reactive oxygen species profile confers chemoresistance in glioma-propagating cells and associates with patient survival outcome.Progenitor-like traits contribute to patient survival and prognosis in oligodendroglial tumors.Applications of stimuli-responsive nanoscale drug delivery systems in translational research.Generation of matched patient-derived xenograft in vitro-in vivo models using 3D macroporous hydrogels for the study of liver cancer.Datasets describing the growth and molecular features of hepatocellular carcinoma patient-derived xenograft cells grown in a three-dimensional macroporous hydrogel.3D Culture as a Clinically Relevant Model for Personalized MedicineEpigenetics of hepatocellular carcinomaAntioxidants: promising neuroprotection against cardiotoxin-4b-induced cell death which triggers oxidative stress with early calpain activationStimuli-Responsive Nanodiamond-Based Biosensor for Enhanced Metastatic Tumor Site DetectionTargeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinomaOptimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP)Nanodiamond-Mediated Delivery of a G9a Inhibitor for Hepatocellular Carcinoma TherapyJAK/STAT signaling in hepatocellular carcinomaDual-Targeting Dual-Action Platinum(IV) Platform for Enhanced Anticancer Activity and Reduced NephrotoxicityNew High-Throughput Screening Identifies Compounds That Reduce Viability Specifically in Liver Cancer Cells That Express High Levels of SALL4 by Inhibiting Oxidative Phosphorylation
P50
Q34435737-E24C0B7E-467F-4E33-B33E-FC3FF9D98CC3Q35100733-FB7D08B0-CAD2-4E25-8FEC-FE8272CE247BQ36585186-7587BB11-FA23-4687-8820-FB7D9C17FAEDQ37618640-0B2974E7-A284-418A-99E7-38FC2C38EED1Q37825330-C8FE417D-0E64-42CB-BFDC-B0AE5636229DQ38724942-520BE699-0B59-405E-8161-DA429F7F1951Q38893018-1D619948-FD58-4856-929D-B21A01DE03C8Q39368430-AF23FD5B-0C1A-4750-8AF2-D9A9910B4EC4Q46012124-5744CC6F-7A2A-46C8-8071-5873142FC104Q47654418-6FA27D06-85D7-485C-BC7F-8782E696327DQ49860312-B8976F65-E1EB-43E2-BD28-A1AABA67CEDDQ49895671-58DE2A22-C48F-400F-BBE5-55928BB9ABDEQ55122627-4D66165D-D99A-44CB-8084-C250DDF2F9AAQ62733901-E791B1E1-848C-4CC9-B12C-9B35A792F3E7Q64240700-15A2456D-ED04-4782-91A8-877489F1ACE2Q80985432-E439B977-EEA7-4469-A71A-085BE202B7FFQ89605801-B9E5629D-5000-421C-9469-E5DB443D114AQ90199717-892BDCE2-78DE-4A2C-9A60-83E5615BE74AQ90839493-F30B1E00-9BB6-4C3C-8F40-13787FE646A5Q91255401-560F67BB-DBBC-4D7B-8731-1F0B803F8ADAQ91791494-8AB9B0A3-225D-4A8A-BF9D-227DE4D106F2Q92838958-55BCC4B2-D27A-4B67-8092-09F91A77EA6CQ92846010-49EA7769-EF0C-436B-9BAE-7D806556E9B1
P50
description
researcher ORCID ID = 0000-0003-0292-6985
@en
wetenschapper
@nl
name
Tan Boon Toh
@ast
Tan Boon Toh
@en
Tan Boon Toh
@es
Tan Boon Toh
@nl
type
label
Tan Boon Toh
@ast
Tan Boon Toh
@en
Tan Boon Toh
@es
Tan Boon Toh
@nl
prefLabel
Tan Boon Toh
@ast
Tan Boon Toh
@en
Tan Boon Toh
@es
Tan Boon Toh
@nl
P108
P106
P1153
23986607500
P31
P496
0000-0003-0292-6985